Analyst Ratings for ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock, with an average price target of $30.5, up by 13.72% from the previous average price target of $26.82. The ratings are generally positive with 9 analysts being indifferent, 5 somewhat bullish, and 4 bullish.
August 22, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a generally positive outlook on ACADIA Pharmaceuticals, with an average price target of $30.5, indicating potential upside.
The average price target of $30.5, which is up by 13.72% from the previous average price target, indicates that analysts see potential upside in the stock. The majority of the ratings are positive, which suggests that analysts have a favorable view of the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100